Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Targeting immunoproteasome-dependent β-catenin degradation as a therapeutic strategy in Relapsed/Refractory acute lymphoblastic leukemia

Jodi Forward, Kadriye Nehir Cosgun, Tianhao Yin, Esma Fera, Deepa Bhojwani, David Teachey, Markus Müschen

Blood (2025) 146 (Supplement 1): 5092.

https://doi.org/10.1182/blood-2025-5092

Published: 2025

Journal Articles

Identifying barriers to clinical trial enrollment for children with relapsed or refractory hematologic malignancies

Blood (2025) 146 (Supplement 1): 4404.

https://doi.org/10.1182/blood-2025-4404

Published: 2025

Journal Articles

Factors associated with central nervous system relapse after b-acute lymphoblastic leukemia: A Children's oncology group report

Blood (2025) 146 (Supplement 1): 762.

https://doi.org/10.1182/blood-2025-762

Published: 2025

Journal Articles

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

Abigale Berry, Caitlin Elgarten, Yimei Li, Hongyan Liu, Katherine Lind, Daniel Zheng, Gabriella Nguyen, Vanessa Fabrizio, Maria Ortega, Jeremy Rubinstein, Troy Quigg, Anurekha Hall, Deepa Bhojwani, Nirali Shah, Shannon Maude, Sara Zarnegar-Lumley, Allison Weisnicht, Keri Toner, Molly Thornock, Stephanie Thomas, Nicholas Tastet, Heather Symons, Jamie Shoag, Amanda Saraf, April Rahrig, Mahvish Rahim, Alexandra Prosser-Dombrowski, Thomas Pfeiffer, Hiren Patel, Megan Murphy, Lindsey Murphy, Amy Moskop, Giselle Moore-Higgs, Jordan Milner, Kevin McNerney, Cathy Lee-Miller, Mira Kohorst, Hannah Kinoshita, Elizabeth Krieger, Smitha Vasanna, Alex Hoover, Ashley Hinson, Miza Salim Hammoud, Darcy Hamill, Erin Goode, Kelly Faulk, Alejandra Escobar Vasco, Lyannette Elo, Anna Elias, Elizabeth Eom, Jennifer Drinkwine, J. Gregory Dolan, Laurie Davis, Roland Chu, Eliza Briscoe, Deepika Bhatla, Jill Beck, Abdulla Al-Mulla, Ibrahim Ahmed, Lena Winestone, Regina Myers

Blood (2025) 146 (Supplement 1): 4525.

https://doi.org/10.1182/blood-2025-4525

Published: 2025

Journal Articles

Direct measurement is required for accurate assessment of body composition during therapy for acute lymphoblastic leukemia: A report from the T2020-003 IDEAL2 trial

Blood (2025) 146 (Supplement 1): 6831.

https://doi.org/10.1182/blood-2025-6831

Published: 2025

Journal Articles

Targeting β-catenin nuclear export and protein degradation in high-risk acute lymphoblastic leukemia

Jodi Forward, Kadriye Nehir Cosgun, Esma Fera, Deepa Bhojwani, David Teachey, Markus Müschen

Blood (2025) 146 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2025-3371

Published: 2025

Journal Articles

Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy

Regina Myers, Yimei Li, Hongyan Liu, Alex Hoover, Laura Shinehouse, Ashley Hinson, Mira Kohorst, Anna Elias, Ella Keenan, Hannah Acres, Ibrahim Ahmed, Abdulla Al-Mulla, Laura Arthur, Jill Beck, Abigale Berry, Deepika Bhatla, Eliza Briscoe, Grace Chang, Roland Chu, Laurie Davis, J. Gregory Dolan, Lyannette Elo, Elizabeth Eom, Alejandra Escobar Vasco, Vanessa Fabrizio, Kelly Faulk, Victor Galan-Gomez, Erin Goode, Stephan Grupp, Anurekha Hall, Darcy Hamill, Smitha Vasanna, Hannah Kinoshita, Elizabeth Krieger, Cathy Lee-Miller, Katherine Lind, Jordan Milner, Giselle Moore-Higgs, Amy Moskop, Lindsey Murphy, Megan Murphy, Gabriella Nguyen, Maria Ortega, Hiren Patel, Antonio Perez, Thomas Pfeiffer, Alexandra Prosser-Dombrowski, Mahvish Rahim, April Rahrig, Shanti Ramachandran, Miza Salim Hammoud, Amanda Saraf, Jamie Shoag, Heather Symons, Nicholas Tastet, Stephanie Thomas, Molly Thornock, Keri Toner, Allison Weisnicht, Sara Zarnegar-Lumley, Nirali Shah, Shannon Maude, Jeremy Rubinstein, Troy Quigg, Deepa Bhojwani, Caitlin Elgarten

Blood (2025) 146 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2025-3339

Published: 2025

Journal Articles

Outcomes after relapse for adolescent and young adult patients with ALL: Results from the Children's oncology group

Jordyn Griffin, Lingyun Ji, Alice Dang, Xinxin Xu, Loretta Li, Naomi Winick, William Carroll, Stephen Hunger, Elizabeth Raetz, Mignon Loh, Michael Borowitz, Brent Wood, Mary Shago, Nyla Heerema, Andrew Carroll, Jennifer McNeer, Deepa Bhojwani, Susan Rheingold

Blood (2025) 146 (Supplement 1): 548.

https://doi.org/10.1182/blood-2025-548

Published: 2025

Journal Articles

A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia

Morgan Drucker, Catherine Aftandilian, Kara Davis, Susan Rheingold, Daisha Ball, Kelly Faulk, Maureen O'Brien, Jamie Stokke, Deepa Bhojwani, Rishi Kotecha, Jeremy Rubinstein

Blood (2025) 146 (Supplement 1): 1570.

https://doi.org/10.1182/blood-2025-1570

Published: 2025

Journal Articles

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Alexander Hamil, Ibrahim Aldoss, Shannon Maude, Ashish Bajel, Armin Ghobadi, Rawan Faramand, Tom Leedom, Michael Rettig, Cherry Thomas, Ayman Kabakibi, Deepa Bhojwani

Blood (2025) 146 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2025-4163

Published: 2025

Journal Articles

Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study

Katherine Lind, Abigale Berry, Yimei Li, Hongyan Liu, Jeremy Rubinstein, Gabriella Nguyen, Vanessa Fabrizio, Anurekha Hall, Deepa Bhojwani, Troy Quigg, Shannon Maude, Nirali Shah, Maria Ortega, Abdulla Al-Mulla, Ibrahim Ahmed, Jill Beck, Deepika Bhatla, Eliza Briscoe, Roland Chu, Laurie Davis, J. Gregory Dolan, Jennifer Drinkwine, Anna Elias, Lyannette Elo, Elizabeth Eom, Kelly Faulk, Erin Goode, Darcy Hamill, Miza Salim Hammoud, Ashley Hinson, Alex Hoover, Hannah Kinoshita, Mira Kohorst, Elizabeth Krieger, Cathy Lee-Miller, Kevin McNerney, Jordan Milner, Amy Moskop, Giselle Moore-Higgs, Lindsey Murphy, Megan Murphy, Hiren Patel, Thomas Pfeiffer, Alexandra Prosser-Dombrowski, Mahvish Rahim, April Rahrig, Amanda Saraf, Jamie Shoag, Heather Symons, Nicholas Tastet, Stephanie Thomas, Molly Thornock, Keri Toner, Smitha Vasanna, Alejandra Escobar Vasco, Allison Weisnicht, Sara Zarnegar-Lumley, Lena Winestone, Regina Myers, Caitlin Elgarten

Blood (2025) 146 (Supplement 1): 6292.

https://doi.org/10.1182/blood-2025-6292

Published: 2025

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Blood (2024) 144 (Supplement 1): 2828.1.

https://doi.org/10.1182/blood-2024-201871

Published: 2024

Journal Articles

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

Blood (2024) 144 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2024-201998

Published: 2024

Journal Articles

A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Amanda M Li, Catherine Aftandilian, Susan Colace, Sarah Fanizzi, Kelly Elizabeth Faulk, Erin M. Guest, Ammar Hayani, Richard Ho, Anjali Khanna, Kasey Leger, David McCall, Tamara P. Miller, Holly Pacenta, Troy Quigg, Jeremy D. Rubinstein, Deepa Bhojwani, Susan R Rheingold, Maureen M. O'Brien, Karen R Rabin

Blood (2024) 144 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2024-209455

Published: 2024

Journal Articles

Metabolomic Profiling of Asparaginase-Induced Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia

Amani Alqahatni, Deepa Bhojwani, Houda Alachkar

Blood (2024) 144 (Supplement 1): 2845.

https://doi.org/10.1182/blood-2024-211306

Published: 2024

Journal Articles

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Yimei Li, Adam Lamble, Emily M. Hsieh, Samuel John, Gregory Dolan, Hongyan Liu, Lee Chen, Jennifer Sheppard, Amanda M. DiNofia, Colleen Annesley, Stephan A. Grupp, Deepa Bhojwani, Rebecca A. Gardner, Lia Gore, Susan R Rheingold, Nirali N. Shah, Michael A. Pulsipher

Blood (2024) 144 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2024-202027

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Blood (2024) 144 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2024-202005

Published: 2024

Journal Articles

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Blood (2024) 144 (Supplement 1): 634.

https://doi.org/10.1182/blood-2024-203756

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting immunoproteasome-dependent β-catenin degradation as a therapeutic strategy in Relapsed/Refractory acute lymphoblastic leukemia

Identifying barriers to clinical trial enrollment for children with relapsed or refractory hematologic malignancies

Factors associated with central nervous system relapse after b-acute lymphoblastic leukemia: A Children's oncology group report

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

Direct measurement is required for accurate assessment of body composition during therapy for acute lymphoblastic leukemia: A report from the T2020-003 IDEAL2 trial

Targeting β-catenin nuclear export and protein degradation in high-risk acute lymphoblastic leukemia

Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy

Outcomes after relapse for adolescent and young adult patients with ALL: Results from the Children's oncology group

A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Metabolomic Profiling of Asparaginase-Induced Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only